002422 Sichuan Kelun Pharmaceutical
- 33.95
- +1.12+3.41%
Sichuan Kelun Pharmaceutical News
Colon Pharmaceutical (002422) 2023 Report Review: Multi-wheel Drive Steady Growth and Innovative Layout Usher in a Harvest Period
Performance summary: In 2023, the company achieved operating income of RMB 21.454 billion (+12.69%), net profit to mother of RMB 2,456 billion (+44.03%), and net profit of non-return to mother of RMB 2,366 billion (+
Colon Pharmaceutical (002422): Performance is in line with expectations, and the large infusion and API sector is growing steadily
Core view In 2023, Colon Pharmaceuticals revenue was 21.454 billion yuan, up 12.69% year on year; net profit was 2,457 billion yuan, up 44.05% year on year. The large infusion segment is the company's revenue pillar, year over year 23
Colon Pharmaceuticals (002422): Rapid performance growth focuses on pipeline clinical and commercialization promotion
The 2023 results are in line with our expectations; 1Q24 slightly exceeded our expectations. The company announced its 2023 results: revenue of RMB 21.45 billion, up 13.4% year on year; net profit to mother of RMB 2.46 billion, up 43 year on year.
Colon Pharmaceutical (002422): Three steps drive performance growth, innovative R&D and efficient promotion
Core view: Incident: The company released its 2023 annual report and the first quarter of 2024:2023 revenue of RMB 21.454 billion, +12.69% YoY; net profit to mother of RMB 2,456 billion, +44.03
Colon Pharmaceutical (002422): Excellent performance in the infusion business, innovation, transformation and acceleration of implementation
Incident: The company released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved operating income of 21.45 billion yuan, an increase of 12.7% over the previous year; net profit to mother was 2.46 billion yuan, an increase of 44% over the previous year
China Galaxy released a research report on April 24 stating that it gave Colon Pharmaceutical (002422.SZ) a recommended rating. The main reasons for the rating include: 1) Infusion continues to exceed expectations, demand is strong & structure is optimize
China Galaxy released a research report on April 24 stating that it gave Colon Pharmaceutical (002422.SZ) a recommended rating. The main reasons for the rating include: 1) Infusion continues to exceed expectations, demand is strong & structure is optimized, and it will continue to grow rapidly in the future; 2) the antibiotic leader is expected to continue to grow rapidly due to sharp rise in volume and price reduction and efficiency; 3) Collombotai's milestone revenue continues to be realized, and SKB264 is ready for commercialization soon. (Mainichi Keizai Shimbun)
Colon Pharmaceuticals (002422): Continued strong trend in 1Q, all sectors attacked at full speed
1Q continued the strong trend of the annual report. All sectors attacked at full speed, with a target price of 43.44 yuan to maintain the “purchase” company's 23 years of achieving restated revenue/net profit of RMB 214.5/2.46 billion yuan (+12.7/44.0
Express News | Colon Pharmaceuticals: Net profit due to mother in 2023 was 2,456 billion yuan, up 44.03% year-on-year
Express News | Nearly 200 companies disclosed first-quarter results forecasts, and it is expected that more than 80% of the companies will be
A-share changes | Q1 performance pre-increased, Colon Pharmaceuticals rose more than 5%, market capitalization nearly 50 billion yuan
Glonghui, April 11 | Colon Pharmaceutical (002422.SZ) rose more than 5%, and its stock price returned above 30 yuan, with a market value of nearly 50 billion yuan. According to the news, the company's net profit for the first quarter was 950 million yuan to 110 billion yuan, an increase of 16.64%-35.06% over the previous year. During the reporting period, the company increased market development and continued to optimize the product structure. Sales of infusion and non-infusion preparations increased, and profits increased year-on-year.
Express News | Colon Pharmaceuticals Performance Report: 2023 net profit increased 44.05% year-on-year
Colon Pharmaceuticals (002422.SZ): The core product, lucansastuzumab (sAC-TMT), published research results at the 2024 American Association for Cancer Research Annual Meeting
Colon Pharmaceuticals (002422.SZ) announced that its holding subsidiary, Sichuan Collenbotai Biomedical Co., Ltd. (“Colunbotai”), will announce its anti-TROP2 ADC lucansatuzumab (sAC-TMT) (formerly SKB264/) at the 2024 American Association for Cancer Research (AACR) Annual Meeting to be held in San Diego, California, USA from April 5 to 10, 2024, at the poster presentation session from 1:30 p.m. to 5:00 p.m. local time on April 9, 2024 CT247 MK-2870) for both
Express News | Midday announcement: Ruihu Mold and Colon Pharmaceuticals suggest that convertible bonds will soon stop converting into shares
Parenteral Nutrition Market Global Analysis and Forecasts to 2030, Featuring Fresenius Kabi, Grifols, Pfizer, Otsuka Pharmaceutical, Baxter, Sichuan Kelun Pharmaceutical, Vifor Pharma and Aculife
Colon Pharmaceutical (002422.SZ): The subsidiary's core product SKB264 (MK-2870) was recognized as a breakthrough therapy by the State Drug Administration for first-line treatment of locally advanced, recurrent, or metastatic PD-L1 negative TNBC that cann
Gelonghui, March 13 | Colon Pharmaceutical (002422.SZ) announced that the company recently learned that the core product SKB264 (also known as MK-2870) of the company's holding subsidiary, Sichuan Colunbotai Biomedical Co., Ltd. (hereinafter referred to as “Columbite”), was recently recognized as a breakthrough therapy by the National Drug Administration (hereinafter referred to as “NMPA”) Drug Evaluation Center (TNBC) for first-line treatment of locally advanced, recurrent, or metastatic PD-L1 negative triple-negative breast cancer (TNBC). This is SKB264 follow-up treatment
US FDA to Accelerate Review of Kelun Pharma Unit's Lung Cancer Drug
The US Food and Drug Administration granted a Fast Track designation for a lung cancer drug developed by Sichuan Kelun Botai Biopharmaceutical, a unit of Sichuan Kelun Pharmaceutical (SHE:002422), acc
Express News | Colon Pharmaceuticals: The subsidiary's main product, A400, was granted Fast Track Qualification by the US Food and Drug Administration
Colon Pharmaceutical (002422.SZ): A new product related to parenteral nutrition obtained drug registration approval
Colon Pharmaceutical (002422.SZ) issued an announcement that in the company's chemical “omega-3 triglycerides (2%)/...
Express News | Colon Pharmaceuticals: Omega-3 triglyceride (2%) medium/long chain fat milk/amino acid (16) /glucose (16%) injection approved for drug registration
Colon Pharmaceutical (002422.SZ): Weight loss products have not yet been deployed
Gelonghui, Feb. 23丨An investor asked Colon Pharmaceuticals (002422.SZ) on the investor interactive platform, “Does your company currently plan to develop diet pills? Or does it already have a layout in the field of diet pills?” The company replied that the company has yet to lay out weight loss products, and the company will actively pay attention to cutting-edge trends in the industry and conduct comprehensive research and judgment.
Analysis
Price Target
No Data
